Drug resistance: Challenges to effective therapy

Current Cancer Drug Targets

Volumn 11, Issue 5, 2011, Pages 613-623

  Shekhar, M P V ^a  

^a WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Acquired and de novo resistance; DNA damage tolerance; Extracellular matrix; Stromal microenvironment; Three dimensional cultures

Indexed keywords

ANTHRACYCLINE; BCR ABL PROTEIN; BRCA1 PROTEIN; CD20 ANTIBODY; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR ALPHA; GEFITINIB; GLYCOPROTEIN P; IMATINIB; MULTIDRUG RESISTANCE PROTEIN 1; RITUXIMAB; TAMOXIFEN; TAXANE DERIVATIVE; TRASTUZUMAB; VASCULOTROPIN RECEPTOR 1; VERAPAMIL;

BREAST CANCER; CANCER CELL; CELL INTERACTION; CELL PROLIFERATION; DNA DAMAGE; DNA DAMAGE TOLERANCE PATHWAY; DRUG HYPERSENSITIVITY; DRUG RESISTANCE; DRUG SENSITIVITY; EXTRACELLULAR MATRIX; FIBROBLAST; GENE EXPRESSION; GENE MUTATION; GENETIC EPISTASIS; HUMAN; IN VIVO STUDY; IONIZING RADIATION; LUNG NON SMALL CELL CANCER; MOLECULARLY TARGETED THERAPY; MONOTHERAPY; MULTIDRUG RESISTANCE; MULTIMODALITY CANCER THERAPY; MUTAGENESIS; MYELOID LEUKEMIA; NONHODGKIN LYMPHOMA; OVARY CANCER; PROCESS MODEL; REVIEW; STROMA CELL; THERAPY RESISTANCE; TUMOR MICROENVIRONMENT; TUMOR SPHEROID; TUMOR SUPPRESSOR GENE;

EID: 79958149328     PISSN: 15680096     EISSN: 18735576     Source Type: Journal    
DOI: 10.2174/156800911795655921     Document Type: Review

References (97)

1. Goldman, J. M.; Melo, J. V. Targeting the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N. Engl. J. Med. 2001, 344, 1804-1806.
2. Nagar, B.; Bornmann, W. G.; Pellicena, P.; Schindler, T; Veach, D. R.; Miller, W. T.; Clarkson, B.; Kuriyan, J. Crystal structures of the kinase domain of c-Abl in complex with the small molecule inhibitors PD173955 and imatinib (STI-571). Cancer Res. 2002, 62, 4236-4243.
3. Kim, R.; Toge, T. Changes in therapy for solid tumors: potential for overcoming drug resistance in vivo with molecular targeting agents. Surg. Today 2004, 34, 293-303.
4. von Bubnoff, N.; Schneller, F.; Peschel, C.; Duyster, J. BCR-ABL gene mutations in relation to clinical resistance of Philadelphiachromosome-positive leukemia to ST1571: a prospective study. Lancet 2002, 359, 487-491.
5. Nimmanapalli, R.; Bhalla, K. Mechanisms of resistance to imatinib mesylate in Bcr-Abl-positive leukemias. Curr. Opin. Oncol. 2002, 14, 616-620.
6. Slamon, D. J.; Leyland-Jones, B.; Shak, S.; Fuchs, H.; Paton, V.; Bajamonde, A.; Fleming, T.; Eiermann, W.; Wolter, J.; Pegram, M.; Baselga, J.; Norton, L. Use of chemotherapy plus a monoclonal antibody against HER2. N. Engl. J. Med. 2001, 344, 783-792.
7. Scaltriti, M.; Eichhorn, P. J.; Cortés, J.; Prudkin, L.; Aura, C.; Jiménez, J.; Chandarlapaty, S.; Serra, V.; Prat, A.; Ibrahim, Y. H.; Guzmán, M.; Gili, M.; Rodríguez, O.; Rodríguez, S.; Pérez, J.; Green, S. R.; Mai, S.; Rosen, N.; Hudis, C.; Baselga, J. Cyclin E amplification/overexpression is a mechanism of trastuzumab resistance in HER2+ breast cancer patients. Proc. Natl. Acad. Sci. USA 2011, 108, 3761-3766.
8. Encarnacion C. A.; Ciocca, D. R.; McGuire, W. L.; Clark, G. M.; Fuqua, S. A.; Osborne, C. K. Measurement of steroid hormone receptors in breast cancer patients on tamoxifen. Breast Cancer Res. Treat. 1993, 26, 237-246.
9. Sharma S. V.; Lee, D. Y.; Li, B.; Quinlan, M. P.; Takahashi, F.; Maheswaran, S.; McDermott, U.; Azizian, N.; Zou, L.; Fischbach, M. A.; Wong, K. K.; Brandstetter, K.; Wittner, B.; Ramaswamy, S.; Classon, M.; Settleman, J. A chromatin-mediated reversible drug-tolerant state in cancer cell subpopulations. Cell 2010, 141, 69-80.
10. Frank, N. Y.; Schatton, T.; Frank, M. H. The therapeutic promise of cancer stem cell concept. J. Clin. Invest. 2010, 120, 41-50.
11. Shekhar, M. P.; Tait, L. Breast cancer stem cell paradigm. In Stem cells and cancer; Parsons, D.W., Ed.; Nova Science Publishers: NY, 2007, pp. 47-64.
12. Paik, S.; Shak, S.; Tang, G.; Kim, C.; Baker, J.; Cronin, M.; Baehner, F. L.; Walker, M. G.; Watson, D.; Park, T.; Hiller, W.; Fisher, E. R.; Wickerham, D. L.; Bryant, J.; Wolmark, N. A multigene assay to predict recurrence of tamoxifen-treated, nodenegative breast cancer. N. Engl. J. Med. 2004, 351, 2817-2826.
13. Yeatman, T. J.; Mule, J.; Dalton, W. S.; Sullivan, D. On the eve of personalized medicine in oncology. Cancer Res. 2008, 68, 7250-7252.
14. Riedel, R. F.; Porrello, A.; Pontzer, E.; Chenette, E. J.; Hsu, D. S.; Balakumaran, B.; Potti, A.; Nevins, J.; Febbo, P. G. A genomic approach to identify molecular pathways associated with chemotherapy resistance. Mol. Cancer Ther. 2008, 7, 3141-3149.
15. Stein, W. D.; Bates, S. E.; Fojo, T. Intractable cancers: The many faces of multidrug resistance and the many targets it presents for therapeutic attack. Curr. Drug Targets 2004, 5, 333-346.
16. Gottesman, M. M. Mechanisms of cancer drug resistance. Ann. Rev. Med. 2002, 53, 615-627.
17. Lowe, S. W.; Ruley, H. E.; Jacks, T; Housman, D. E. p53 dependent apoptosis modulates the cytotoxicity of anticancer agents. Cell 1993, 74, 957-967.
18. Szakacs, G.; Paterson, J. K.; Ludwig, J.; Booth-Genthe, C.; Gottesman, M. M. Targeting multidrug resistance in cancer. Nat. Rev. Drug Discovery 2006, 5, 219-234.
19. Merry, S.; Courtney, E. R.; Fetherston, C. A.; Kaye, S. B.; Freshney, R. I. Circumvention of drug resistance in human nonsmall lung cancer in vitro by verapamil. Br. J. Cancer 1987, 56, 401-405.
20. Fojo, A.; Hamilton, T. C.; Young, R. C.; Ozols, R. F. Multidrug resistance in ovarian cancer. Cancer 1987, 60(Suppl 8), 2075-2080.
21. Rustum, Y. M.; Radel, S.; Campbell, J.; Mayhew, E. Approaches to overcome in vivo anti-cancer drug resistance. Prog. Clin. Biol. Res. 1986, 223, 187-202.
22. Zhou, S.; Schuetz, J. D.; Bunting, K. D.; Colapietro, A. M.; Sampath, J.; Morris, J. J.; Lagutina, I.; Grosveld, G. C.; Osawa, M.; Nakauchi, H.; Sorrentino, B. P. The ABC transporter Bcrp1/ABCG2 is expressed in a wide variety of stem cells and is a molecular determinant of the side-population phenotype. Nat. Med. 2001, 7, 1028-1034.
23. Nobilit, S.; Landini, I.; Giglioni, B.; Mini, E. Pharmacological strategies for overcoming multidrug resistance. Curr. Drug Targets 2006, 7, 861-879.
24. Takara, K.; Sakaeda, T.; Okumura, K. An update on overcoming MDR1-mediated multidrug resistance in cancer chemotherapy. Curr. Pharm. Des. 2006, 12, 273-286.
25. Chavanpatil, M. D.; Khdair, A.; Gerard, B.; Bachmeier, C.; Miller, D. W.; Shekhar, M. P.; Panyam, J. Surfactant-polymer nanoparticles overcome P-glycoprotein-mediated drug efflux. Mol. Pharm. 2007, 4, 730-738.
26. Khdair, A.; Chen, D.; Patil, Y.; Ma, L.; Dou, Q. P.; Shekhar, M. P.; Panyam, J. Nanoparticle-mediated combination chemotherapy and photodynamic therapy overcomes tumor drug resistance. J. Control Release 2010, 141, 137-144.
27. Devalapally, H.; Duan, Z.; Seiden, M. V.; Amiji, M. M. Modulation of drug resistance in ovarian adenocarcinoma by enhancing intracellular ceramide using tamoxifen-loaded biodegradable polymeric nanoparticles. Clin. Cancer Res. 2008, 14, 3193-3203.
28. Koziara, J. M.; Whisman, T. R.; Tseng, M. T.; Mumper, R. J. Invivo efficacy of novel paclitaxel nanoparticles in paclitaxelresistant human colorectal tumors. J. Control Release 2006, 112, 312-319.
29. Tran, M. A.; Smith, C. D.; Kester, M.; Robertson, G. P. Combining nanoliposomal ceramide with sorafenib synergistically inhibits melanoma and breast cancer cell survival to decrease tumor development. Clin. Cancer Res. 2008, 14, 3571-3581.
30. Friedberg, E.; Graham, C.; Siede, W. DNA Repair and Mutagenesis. American Society for Microbiology, Washington D.C., 1995.
31. Wiltshire, T.; Senft, J.; Wang, Y.; Konat, G. W.; Wenger, S. L.; Reed, E.; Wang, W. BRCA1 contributes to cell cycle arrest and chemoresistance in response to anticancer agent, irofulven. Mol. Pharmacol. 2007, 71, 1051-1060.
32. Broomfield, S.; Hryciw, T.; Xiao, W. DNA postreplication repair and mutagenesis in Saccharomyces cerevisiae. Mutat. Res. 2001, 486, 167-184.
33. Kunz, B. A.; Straffon, A. F.; Vonarx, E. J. DNA damage-induced mutation: tolerance via translesion synthesis. Mutat. Res. 2000, 451, 169-185.
34. McDonald, J. P.; Levine, A. S.; Woodgate, R. The Saccharomyces cerevisiae RAD30 gene, a homologue of Escherichia coli dinB and umuC, is DNA damage inducible and functions in a novel errorfree postreplication repair mechanism. Genetics 1997, 147, 1557-1568.
35. Nelson, J. R.; Lawrence, C. W.; Hinkle, D. C. Thymine-thymine dimer bypass by yeast DNA polymerase zeta. Science 1996, 272, 1646-1649.
36. Lawrence, C. W.; Christensen, R. UV mutagenesis in radiationsensitive strains of yeast. Genetics 1976, 82, 207-232.
37. Prakash, L. Characterization of postreplication repair in Saccharomyces cerevisiae and effects of rad6, rad18, rev3 and rad52 mutations. Mol. Gen. Genet. 1981, 184, 471-478.
38. Bailly, V.; Lamb, J.; Sung, P.; Prakash, S.; Prakash, L. Specific complex formation between yeast RAD6 and RAD18 proteins: a potential mechanism for targeting RAD6 ubiquitin-conjugating activity to DNA damage sites. Genes Dev. 1994, 8, 811-820.
39. Bailly, V.; Prakash, P. Domains required for dimerization of yeast Rad6 ubiquitin-conjugating enzyme and Rad18 DNA binding protein. Mol. Cell. Biol. 1997, 17, 4536-4543.
40. Hoege, C.; Pfander, B.; Moldovan, G. L.; Pyrowolakis, G.; Jentsch, S. RAD6-dependent DNA repair is linked to modification of PCNA by ubiquitin and SUMO. Nature 2002, 419, 135-141.
41. Friedberg, E. C.; Lehmann, A. R.; Fuchs, R. P. P. Trading places: How do DNA polymerases switch during translesion DNA synthesis. Mol. Cell 2005, 18, 499-505.
42. Koken, M. H.; Reynolds, P.; Jaspers-Dekker, I.; Prakash, L.; Prakash, S.; Bootsma, D.; Hoeijmakers, J. H. Structural and functional conservation of two human homologs of the yeast DNA repair gene RAD6. Proc. Natl. Acad. Sci. USA 1991, 88, 8865-8869.
43. Koken, M. H.; Smit, E. M.; Jaspers-Dekker, I.; Oostra, B. A.; Hagemeijer, A.; Bootsma, D.; Hoeijmakers, J. H. Localization of two human homologs, HHR6A and HHR6B, of the yeast DNA repair gene RAD6 to chromosomes Xq24-q25 and 5q23-q31. Genomics 1992, 12, 447-453.
44. Roest, H. P.; Baarends, W. M.; de Wit, J.; van Klaveren, J. W.; Wassenaar, E.; Hoogerbrugge, J. W.; van Cappellen, W. A.; Hoeijmakers, J. H.; Grootegoed, J. A. The ubiquitin-conjugating DNA repair enzyme HR6A is a maternal factor essential for early embryonic development in mice. Mol. Cell. Biol. 2004, 24, 5485-5495.
45. Sung, P.; Prakash, S.; Prakash, L. Mutation of cysteine-88 in the Saccharomyces cerevisiae RAD6 protein abolishes its ubiquitinconjugating activity and its various biological functions. Proc. Natl. Acad. Sci. USA 1990, 87, 2695-2699.
46. Sung, P., Prakash, S.; Prakash L. Stable ester conjugate between the Saccharomyces cerevisiae RAD6 protein and ubiquitin has no biological activity. J. Mol. Biol. 1991, 221, 745-749.
47. Prakash, S.; Sung, P.; Prakash, L. Structure and function of RAD3, RAD6, and other DNA repair genes of Saccharomyces cerevisiae. In The eukaryotic nucleus; Strauss, P.R.; Wilson, S.H.; Ed.; Telford Press: Caldwell, NJ, 1990; Vol. 1, pp. 275-292.
48. Shekhar, M. P.; Lyakhovich, A.; Visscher, D. W.; Heng, H.; Kondrat, N. Rad6 overexpression induces multinucleation, centrosome amplification, abnormal mitosis, aneuploidy, and transformation. Cancer Res. 2002, 62, 2115-2124.
49. Lyakhovich, A.; Shekhar, M. P. RAD6B overexpression confers chemoresistance: RAD6 expression during cell cycle and its redistribution to chromatin during DNA damage-induced response. Oncogene 2004, 23, 3097-3106.
50. Shekhar, M. P.; Tait, L.; Gerard, B. Essential role of T-cell factor/beta-catenin in regulation of Rad6B: a potential mechanism for Rad6B overexpression in breast cancer cells. Mol Cancer Res. 2006, 4, 729-745.
51. Myung, K.; Smith, S. The RAD5-dependent postreplication repair pathway is important to suppress gross chromosomal rearrangements. JNCI Monogr. 2008, 39, 12-15.
52. Boyer, J. C.; Kaufman, W. K.; Brylawski, B. P.; Cordeiro-Stone, M. Defective postreplication repair in xeroderma pigmentosum variant fibroblasts. Cancer Res, 1990, 50, 2593-2598.
53. Masutani, C.; Kusumoto, R.; Yamada, A.; Yuasa, M.; Araki, M.; Nogimori, T.; Yokoi, M.; Eki, T.; Iwai, S.; Hanaoka, F. Xeroderma pigmentosum variant: from a human genetic disorder to a novel DNA polymerase. Cold Spring Harb. Symp. Quant. Biol. 2000, 65, 71-80.
54. Motegi, A.; Sood, R.; Helen, M.; Markowitz, S. D.; Liu, P. P.; Myung, K. Human SHPRH suppresses genomic instability through proliferating cell nuclear antigen polyubiquitination. J. Cell Biol. 2006, 175, 703-708.
55. Sood, R.; Makalowska, I.; Galdzicki, M.; Hu, P.; Eddings, E.; Robbins, C. M.; Moses, T.; Namkoong, J.; Chen, S.; Trent, J. M. Cloning and characterization of a novel gene, SHPRH, encoding a conserved putative protein with SNF2/helicase and PHD-finger domains from the 6q24 region. Genomics 2003, 82, 153-161.
56. Tateishi, S.; Niwa, H.; Miyazaki, J.; Fujimoto, S.; Inoue, H.; Yamaizum, M. Enhanced genomic instability and defective postreplication repair in Rad18 knockout mouse embryonic stem cells. Mol. Cell. Biol. 2003, 23, 474-481.
57. Senan, S.; De Ruysscher, D.; Giraud, P.; Mirimanoff, R.; Budach, V. Literature-based recommendations for treatment planning and execution in high-dose radiotherapy for lung cancer. Radiother. Oncol. 2004, 71, 139-146.
58. Soffietti, R.; Ruda, R.; Mutani, R. Management of brain metastases. J. Neurol. 2002, 249, 1357-1369.
59. Beir, V. Health effects of exposure to low levels of ionizing radiation. National Academy Press, Washington D.C., 1990.
60. Brada, M.; Ford, D.; Ashley, S.; Bliss, J. M.; Crowley, S.; Mason, M.; Rajan, B.; Traish, D. Risk of second brain tumor after conservative surgery and radiotherapy for pituitary adenoma. BMJ. 1992, 304, 1343-1346.
61. Kimball, D. V. M.; Gelber, R. D.; Li, F.; Donnelly, M. J.; Tarbell, N. J.; Sallan, S. E. Second malignancies in patients treated for childhood acute lymphoblastic leukemia J. Clin. Oncol. 1998, 16, 2848-2853.
62. Sadetzki, S.; Flint-Richter, P.; Ben-Tal, T.; Nass, D. Radiationinduced meningioma: a descriptive study of 253 cases. J. Neurosurg. 2002, 97, 1078-1082.
63. Lin, X.; Okuda, T.; Trang, J.; Howell, S. B. hREV1 modulates the cytotoxicity and mutagenicity of cisplatin in human ovarian carcinoma cells. Mol. Pharmacol. 2006, 69, 1748-1754.
64. Okuda, T.; Lin, X.; Trang, J.; Howell, S. B. Suppression of hREV1 expression reduces the rate at which human ovarian carcinoma cells acquire resistance to cisplatin. Mol. Pharmacol. 2005, 67, 1852-1860.
65. Chen, C. C.; Motegi, A.; Hasegawa, Y.; Myung, K.; Kolodner, R.; D'Andrea A. Genetic analysis of ionizing radiation-induced mutagenesis in Saccharomyces cerevisiae reveals translesion synthesis (TLS) independent of PCNA K164 SUMOylation and ubiquitination. DNA Repair 2006, 5, 1475-1488.
66. Berkers C. R.; Ovaa, H. Drug discovery and assay development in the ubiquitin-proteasome system. Biochem. Soc. Trans. 2010, 38, 14-20.
67. Arastu-Kapur, S.; Anderl, J. L.; Kraus, M.; Parlati, F.; Shenk, K. D.; Lee, S. J.; Muchamuel, T.; Bennett, M. K.; Driessen, C.; Ball, A. J.; Kirk, C. J. Non-proteasomal targets of the proteasome inhibitors bortezomib and carfilzomib: a link to clinical adverse events. Clin. Cancer Res. 2011, March 1 [Epub ahead of print].
68. Li, Z-W.; Dalton, W. S. Tumor microenvironment and drug resistance in hematologic malignancies. Blood Reviews 2006, 20, 333-342.
69. Durand, R. E.; Sutherland, R. M. Effects of intercellular contact on repair of radiation damage. Exp. Cell. Res. 1972, 71, 75-80.
70. Green, S. K.; Francia, G.; Isidoro, C.; Kerbel, R. S. Antiadhesive antibodies targeting E-cadherin-sensitize multicellular tumor spheroids to chemotherapy in vitro. Mol. Cancer Ther. 2004, 3, 149-159.
71. Croix, St. B.; Kerbel, R. S. Cell adhesion and drug resistance in cancer. Curr. Opin. Oncol. 1997, 9, 549-556.
72. Stupack, D. G.; Cheresh, D. A. Get a ligand, get a life: integrins, signaling and cell survival. J. Cell Sci. 2002, 115, 3729-3738.
73. Jin, H.; Varner, J. Integrins: roles in cancer development and as treatment targets. Br. J. Cancer 2004, 90, 561-565.
74. Frisch, S. M.; Screaton, R. A. Anoikis mechanisms. Curr. Opin. Cell. Biol. 2001, 13, 555-562.
75. Hoyt, D. G.; Rusnak, J. M.; Mannix, R. J.; Modzelewski, R. A.; Johnson, C. S.; Lazo, J. S. Integrin activation suppresses etoposideinduced DNA strand breakage in cultured murine tumor-derived endothelial cells. Cancer Res. 1996, 56, 4146-4149.
76. Ferber, I.; Bachmann, S. O.; Specht, H.; Wimmel, A.; Gross, M. W.; Schlegel, J.; Suske, G.; Schuermann, M. In vitro chemo-and radio-resistance in small cell lung cancer correlates with cell adhesion and constitutive activation of AKT and MAP kinase pathways. Oncogene 2002, 21, 8683-8695.
77. Kouniavsky, G.; Khaikin, M.; Zvibel, I.; Zippel, D.; Brill, S.; Halpern, Z.; Papa, M. Stromal extracellular matrix reduces chemotherapy-induced apoptosis in colon cancer cell lines. Clin. Exp. Metast 2002, 19, 55-60.
78. Maubant, S.; Cruet-Hennequart, S.; Poulain, L.; Carreiras, F.; Sichel, F.; Luis, J.; Staedel, C.; Gauduchon, P. Altered adhesion properties and alphav integrin expression in a cisplatin-resistant human ovarian carcinoma cell line. Int. J. Cancer 2002, 97, 186-194.
79. Sethi, T.; Rintoul, R. C.; Moore, S. M.; MacKinnon, A. C.; Salter, D.; Choo, C.; Chilvers, E. R.; Dransfield, I.; Donnelly, S. C.; Strieter, R.; Haslett, C. Extracellular matrix proteins protect small cell lung cancer cells against apoptosis: a mechanism for small cell lung cancer growth and drug resistance in vivo. Nat. Med. 1999, 5, 662-668.
80. Weaver, V. M.; Lelièvre, S.; Lakins, J. N.; Chrenek, M. A.; Jones, J. C.; Giancotti, F.; Werb, Z.; Bissell, M. J. beta4 integrindependent formation of polarized three-dimensional architecture confers resistance to apoptosis in normal and malignant mammary epithelium. Cancer Cell 2002, 2, 205-216.
81. Zahir, N.; Weaver, V. M. Death in the third dimension: apoptosis regulation and tissue-architecture. Curr. Opin. Genet. Dev. 2004, 14, 71-80.
82. Wang, C. Y.; Mayo, M. W.; Baldwin, A. S. Jr. TNF-BBBand cancer therapy-induced apoptosis: potentiation by inhibition of NFkappaB. Science 1996, 274, 784-787.
83. Kalluri, R. Basement membranes: structure, assembly, and role in tumor angiogenesis. Nat. Rev. Cancer 2003, 3, 422-433.
84. Sherman-Baust, C. A.; Weeraratna, A. T.; Rangel, L. B.; Pizer, E. S.; Cho, K. R.; Schwartz, D. R.; Shock, T.; Morin, P. J. Remodeling of the extracellular matrix through overexpression of collagen VI contributes to cisplatin resistance in ovarian cancer cells. Cancer Cell 2003, 3, 377-386.
85. Jain, R. K. Vascular and interstitial barriers to delivery of therapeutic agents in tumors. Cancer Metast. Rev. 1990, 9, 253-266.
86. Tannock, I. F.; Lee, C. M.; Tunggal, J. K.; Cowan, D. S.; Egorin, M. J. Limited penetration of anticancer drugs through tumor tissue: a potential cause of resistance of solid tumors to chemotherapy. Clin. Cancer Res. 2002, 8, 878-884.
87. Frassanito, M. A.; Cusmai, A.; Iodice, G.; Dammacco, F. Autocrine interleukin-6 production and highly malignant multiple myeloma: relation with resistance to drug-induced apoptosis. Blood 2001, 97, 483-489.
88. Borsellino, N.; Belldegrun, A.; Bonavida, B. Endogenous interleukin 6 is a resistance factor for cisdiamminedichloroplatinum and etoposide-mediated cytotoxicity of human prostate carcinoma cell lines. Cancer Res. 1995, 55, 4633-4639.
89. Conze, D.; Weiss, L.; Regen, P. S.; Bhushan, A.; Weaver, D.; Johnson, P.; Rincón, M. Autocrine production of interleukin 6 causes multidrug resistance in breast cancer cells. Cancer Res. 2001, 61, 8851-8858.
90. Jankowski, K.; Kucia, M.; Wysoczynski, M.; Reca, R.; Zhao, D.; Trzyna, E.; Trent, J.; Peiper, S.; Zembala, M.; Ratajczak, J.; Houghton, P.; Janowska-Wieczorek, A.; Ratajczak, M.Z. Both hepatocyte growth factor (HGF) and stromal-derived factor-1 regulate the metastatic behavior of human rhabdomyosarcoma cells, but only HGF enhances their resistance to radiochemotherapy. Cancer Res. 2003, 63, 7926-7935.
91. Guo, Y. S.; Jin, G. F.; Houston, C. W.; Thompson, J. C.; Townsend, C. M. Jr. Insulin-like growth factor-I promotes multidrug resistance in MCLM colon cancer cells. J. Cell Physiol. 1998, 175, 141-148.
92. Miyake, H.; Hara, I.; Gohji, K.; Yoshimura, K.; Arakawa, S.; Kamidono, S.; Expression of basic fibroblast growth factor is associated with resistance to cisplatin in a human bladder cancer cell line. Cancer Lett. 1998, 123, 121-126.
93. Navolanic, P. M.; Steelman, L. S.; McCubrey, J. A. EGFR family signaling and its association with breast cancer development and resistance to chemotherapy. Int. J. Oncol. 2003, 22, 237-252.
94. Alexia, C.; Fallot, G.; Lasfer, M.; Schweizer-Groyer, G.; Groyer, A. An evaluation of the role of insulin-like growth factors (IGF) and of type-I IGF receptor signalling in hepatocarcinogenesis and in the resistance of hepatocarcinoma cells against drug-induced apoptosis. Biochem. Pharmacol. 2004, 68, 1003-1015.
95. Shekhar, M. P.; Santner, S.; Carolin, K. A.; Tait, L. Direct involvement of breast tumor fibroblasts in the modulation of tamoxifen sensitivity. Am. J. Pathol. 2007, 170, 1546-1560.
96. Shekhar, M. P.; Werdell, J.; Santner, S. J.; Pauley, R. J.; Tait, L. Breast stroma plays a dominant regulatory role in breast epithelial growth and differentiation: implications for tumor development and progression. Cancer Res. 2001, 61, 1320-1326.
97. Meng, Q. Three-dimensional culture of hepatocytes for prediction of hepatocyte drug-induced hepatotoxicity. Expert Opin. Drug Metab. Toxicol. 2010, 6, 733-746.